Journal of Thrombosis and Thrombolysis

Article	Citations
COVID-19 update: Covid-19-associated coagulopathy	474
Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum	316
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2	229
COVID-19-associated vasculitis and vasculopathy	208
COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature	187
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors	180
Neutrophil extracellular traps and thrombosis in COVID-19	173
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia	152
Heparin resistance in COVID-19 patients in the intensive care unit	129
The association between treatment with heparin and survival in patients with Covid-19	126
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients	117
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis	109
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis	81
Anticipating the long-term cardiovascular effects of COVID-19	79
Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19	73
COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness	67
Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report	65
Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients	64
Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis	64
High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?	61
Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy	60
Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19	58
DVT incidence and risk factors in critically ill patients with COVID-19	58
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review	57
Anticoagulant treatment in COVID-19: a narrative review	56

Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients	52
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE	51
Risk factors for intracerebral hemorrhage in patients with COVID-19	47
Covid-19 treatment update: follow the scientific evidence	42
Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19	40
COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis	39
COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?	38
Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis	38
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19	38
Incidence of thrombotic complications in COVID-19	37
Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19	36
In vivo demonstration of microvascular thrombosis in severe COVID-19	36
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series	36
Pulmonary thrombosis in Covid-19: before, during and after hospital admission	34
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis	33
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus	32
Thrombophilia screening revisited: an issue of personalized medicine	32
Rotational thromboelastometry results are associated with care level in COVID-19	31
Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis	31
Major bleeding complications in critically ill patients with COVID-19 pneumonia	30
The administration of rtPA before mechanical thrombectomy in acute ischemic stroke patients is associated with a significant reduction of the retrieved clot area but it does not influence revasculariz	29
Immature platelets in patients hospitalized with Covid-19	29
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting	29
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients	27
Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19	27
Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report	27
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	27
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis	27
Impact of the COVID-19 pandemic on hyperacute stroke treatment: experience from a comprehensive stroke centre in Singapore	27
Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis	27
SARS-CoV-2 infection and thrombotic complications: a narrative review	26
COVID-19 and its sequelae: a platform for optimal patient care, discovery and training	26
Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines	25
The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells	24
Impact of Coronavirus Disease 2019 outbreak on acute coronary syndrome admissions: four weeks to reverse the trend	24
Sudden death due to acute pulmonary embolism in a young woman with COVID-19	24
Successful use of tPA for thrombolysis in COVID related ARDS: a case series	24
Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products	22
Thromboelastography findings in critically ill COVID-19 patients	22
Aortic thrombus in patients with severe COVID-19: review of three cases	22
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy	22
Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic	22
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19	20
Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel	20
External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19	20
Toward understanding the 2019 Coronavirus and its impact on the heart	20
Value-based assessment of implementing a Pulmonary Embolism Response Team (PERT)	20
Increased intracranial hemorrhage of mechanical thrombectomy in acute ischemic stroke patients with atrial fibrillation	19
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation	19
A comprehensive review of vascular complications in COVID-19	19

Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19	19
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation	19
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage	19
Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review	18
Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease	18
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines	18
Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?	18
Serotonin: a platelet hormone modulating cardiovascular disease	18
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data	17
High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards	17
Physical exertion as a trigger of acute coronary syndrome caused by plaque erosion	17
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients	17
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)	17
Thrombosis in VEXAS syndrome	17
Filter clotting with continuous renal replacement therapy in COVID-19	17
Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?	17
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design	17
Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic	16
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	16
Lupus anticoagulant and mortality in patients hospitalized for COVID-19	16
Arterial and venous involvement in Behçet’s syndrome: a narrative review	16
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis	16
Clinical significance of healed plaque detected by optical coherence tomography: a 2-year follow-up study	15
Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia	15
Significant reductions in apoptosis-related proteins (HSPA6, HSPA8, ITGB3, YWHAH, and PRDX6) are involved in immune thrombocytopenia	15
Acute pulmonary embolism in COVID-19 related hypercoagulability	15
Hyperacute multi-organ thromboembolic storm in COVID-19: a case report	15
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19	14
Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery	14
Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate	14
Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study	14
Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review	14
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019	14
ST-segment elevation in patients with COVID-19: a systematic review	14
Roles of factor Xa beyond coagulation	14
Association of ABO blood group type with cardiovascular events in COVID-19	14
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation	14
A case of thrombotic thrombocytopenic purpura associated with COVID-19	14
Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis	14
Predictors for layered coronary plaques: an optical coherence tomography study	14
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics	13
Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue nacrosis factor-α induced nuclear factor-κappa B signal	13
Circadian variations in pathogenesis of ST-segment elevation myocardial infarction: an optical coherence tomography study	13
Occurrence of pulmonary embolism related to COVID-19	13
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population	13
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19	13
Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation	13
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies	13
Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis	13
Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis	13
PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases	12
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients	12
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia	12
Mitochondria and chronic effects of cancer therapeutics: The clinical implications	12
Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis	12
The clinical characteristic, diagnosis, treatment, and prognosis of cerebral cortical vein thrombosis: a systematic review of 325 cases	12
Prior use of anticoagulation is associated with a better survival in COVID-19	12
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic	12
COVID 19 infection associated with thrombotic thrombocytopenic purpura	12
LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway	11
Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension	11
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	11
Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection	11
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis	11
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism	11
Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients	11
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease	11
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome	11
Risk factors of postoperative deep vein thrombosis (DVT) under low molecular weight heparin (LMWH) prophylaxis in patients with thoracolumbar fractures caused by high-energy injuries	11
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis	11
The Impact of platelet–fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease	11
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?	10
Excessive fibrinolysis detected with thromboelastography in a case of amniotic fluid embolism: fibrinolysis may precede coagulopathy	10
Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis	10
Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway	10
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	10
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography	10
COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles	10
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	10
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis	10

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor	10
Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study	10
Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study	10
Impact of the pandemic of COVID-19 on emergency attendance for stroke and acute myocardial infarction in Beijing, China	10
Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management	10
The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm	9
The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury	9
Overexpression of miR-1298 attenuates myocardial ischemia–reperfusion injury by targeting PP2A	9
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	9
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?	9
Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients	9
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes	9
Differentiating biochemical from clinical heparin resistance in COVID-19	9
Concerns for management of STEMI patients in the COVID-19 era: a paradox phenomenon	9
Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score	9
Treatment of platelet concentrates with the L-carnitine modulates platelets oxidative stress and platelet apoptosis due to mitochondrial reactive oxygen species reduction and reducing cytochrome C rel	9
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis	9
Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic	9
Neurological manifestations of thrombotic microangiopathy syndromes in adult patients	9
Immature platelets in patients with Covid-19: association with disease severity	9
Reducing state attenuates ectodomain shedding of GPVI while restoring adhesion capacities of stored platelets: evidence addressing the controversy around the effects of redox condition on thrombosis	9
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction	8
Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement	8
Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm	8
Downregulating LncRNA XIST attenuated contrast-induced nephropathy injury via regulating miR-133a-3p/NLRP3 axis	8
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer	8
Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study	8
Inflammatory cytokines enhance procoagulant activity of platelets and endothelial cells through phosphatidylserine exposure in patients with essential hypertension	8
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors	8
International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests	8
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study	8
Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)	8
Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome	8
Cellular model systems to study cardiovascular injury from chemotherapy	8
Left atrial appendage closure: a balanced management of the thromboembolic risk in patients with hemophilia and atrial fibrillation	8
Causal effect of renal function on venous thromboembolism: a two-sample Mendelian randomization investigation	8
Point-of-care testing of coagulation in patients treated with edoxaban	8
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality	8
MicroRNA-29b reduces myocardial ischemia–reperfusion injury in rats via down-regulating PTEN and activating the Akt/eNOS signaling pathway	8
Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus	8
Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure	7
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes	7
Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation	7
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri	7
Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation	7
Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban	7
Prognostic implications of the rapid recruitment of coronary collaterals during ST elevation myocardial infarction (STEMI): a meta-analysis of over 14,000 patients	7
The genetics of venous thromboembolism: a systematic review of thrombophilia families	7
LncRNA BANCR induced vascular smooth muscle cell proliferation by downregulating miR-34c methylation in atherosclerosis	7
Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics	7
MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation	7
Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson’s syndrome	7
Global coagulation assays in hypercoagulable states	7
Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series	7
Albumin and bleed risk in rivaroxaban treated patients	7
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective	7
Screening for venous thromboembolism in patients with COVID-19	7
Degree of luminal narrowing and composition of thrombus in plaque erosion	7
Tissue factor: a neglected role in cancer biology	7
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA	7
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing	7
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study	7
National trends in tranexamic acid use in the peripartum period, 2015–2019	7
The impact of proton therapy on cardiotoxicity following radiation treatment	7
Can a modified-simplified pulmonary embolism severity index (m-sPESI) be used to predict the need for intensive care in hospitalized COVID-19 patients?	7
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding	7
Vascular-specific epicardial adipose tissue in predicting functional myocardial ischemia for patients with stable chest pain	7
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of	7
Switching between direct oral anticoagulants: a systematic review and meta-analysis	7
Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: epidemiology, outcomes, and diagnostic challenges	7
Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer	7
A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer	7
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)	7
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity	6
Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation	6
Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors	6
Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event	6
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	6
Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey	6
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	6
Patient-guided modifications of oral anticoagulant drug intake during Ramadan fasting: a multicenter cross-sectional study	6
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	6
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study	6
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction	6
Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 d	6
Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation	6
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial	6
Ultrasound-assisted catheter-directed thrombolysis versus systemic anticoagulation alone for submassive pulmonary embolism	6
Ecchymosis in critical coronavirus disease 2019 (COVID-19) patient in Tangerang, Indonesia: a case report	6
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE tr	6
Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study	6
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	6
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19	6
Routine surveillance of pelvic and lower extremity deep vein thrombosis in stroke patients with patent foramen ovale	6
Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid	6